Abstract
This editorial discusses the findings of Elbarky et al on the role of selenoprotein P1 (SEPP1) in pediatric obesity and insulin resistance. Their study uncovered significantly lower SEPP1 Levels in children who were obese compared with healthy peers, demonstrating a negative correlation between SEPP1 levels and measures of adiposity and insulin resistance. These findings suggest that SEPP1 is a biomarker useful in the early identification of insulin resistance in pediatric populations. This editorial emphasizes the clinical implications of the study and calls for further research to validate and explore the role of SEPP1 in metabolic health.